By Nervana Medical – Mental Health & Integrative Wellness Clinic, Sandy, Utah
Stress is part of everyday life; but when it becomes constant, it can change how your brain and body function. Chronic stress impacts mood, sleep, hormones, and even the way your brain processes emotions. For some people, the effects become overwhelming and lead to anxiety, burnout, or depression.
At Nervana Medical, we specialize in advanced therapies that help restore balance to the brain and body; including ketamine-assisted treatment, which is showing exciting results in improving stress resilience and mood regulation.
What We Know About Ketamine and Stress
Current research shows that ketamine may help reduce the effects of stress on the brain and promote recovery from stress-related conditions such as anxiety, depression, or post-traumatic stress disorder (PTSD).
In both laboratory and clinical settings, ketamine has been found to:
- Rapidly reduce anxiety and depressive symptoms
- Enhance resilience to stress, improving emotional stability and coping ability.
- Promote healthy brain communication, including restoring pathways involved in mood, motivation, and emotional regulation.
These effects are thought to occur through modulation of glutamate and serotonin systems, increasing synaptic plasticity and your brain’s ability to form new, healthier connections. In simpler terms, ketamine helps “reset” parts of the brain that have been worn down by chronic stress or trauma.
What Patients Report
In studies and in real-world clinics, many patients describe:
- Feeling lighter, calmer, or less overwhelmed within hours or days of treatment.
- Improved sleep, motivation, and mental clarity.
- A greater sense of resilience; the ability to handle daily stressors without becoming emotionally flooded.
These benefits can appear quickly, which is one reason ketamine has become a promising option for individuals who haven’t responded well to traditional treatments such as SSRIs or therapy alone.
Who Might Benefit
While research continues to evolve, ketamine may be helpful for individuals struggling with:
- Chronic stress and burnout
- Anxiety or panic symptoms
- Post-traumatic stress disorder (PTSD)
- Depression that has not improved with other therapies
At Nervana Medical, our providers carefully screen each patient to determine whether ketamine therapy is an appropriate and safe option. Factors such as your medical history, current medications, and emotional readiness all play an important role in determining eligibility.
Safety and Ongoing Research
Ketamine is an FDA-approved medication for anesthesia and has an established safety record when administered in a controlled medical setting. Its use for mood and stress-related conditions is considered an “off-label” therapeutic application, supported by growing scientific evidence and clinical experience.
Research continues to explore optimal dosing, long-term outcomes, and best practices for integrating ketamine into comprehensive mental health care. At Nervana Medical, every treatment plan is personalized and overseen by experienced medical professionals to ensure safety and effectiveness.
Why Consultation Matters
Every patient’s story is different. A thorough consultation allows our team to:
- Assess whether you’re a candidate for ketamine therapy
- Review your goals, mental health history, and prior treatments
- Determine the safest route (IV, IM, or oral (troche) ketamine; and customize your care plan
If ketamine isn’t the best fit, we can explore alternative or adjunctive treatments such as hormone optimization, vitamin therapy, or integrative psychotherapy.
The Bottom Line
Early research shows that ketamine can help the brain recover from chronic stress and improve emotional resilience. For many people, it offers a new path toward balance when traditional treatments haven’t worked.
If you’re struggling with stress, anxiety, or burnout, a consultation with one of our experienced providers can help determine whether ketamine therapy is right for you.
References
- Flowers JC et al. FASEB J. 2025;39(16):e70891.
- Camargo A et al. Mol Psychiatry. 2025;30(6):2504–2516.
- Rincó-Cortés M, Grace AA. Behav Brain Res. 2020;379:112367.
- Camargo A et al. Prog Neuropsychopharmacol Biol Psychiatry. 2022;115:110509.
- Dutton M et al. J Affect Disord. 2022;300:410–417.
- Tully JL et al. Br J Clin Pharmacol. 2022;88(10):4412–4426.
- Truppman Lattie D et al. J Psychopharmacol. 2021;35(2):137–141.
- Feder A et al. JAMA Psychiatry. 2014;71(6):681–688.
- Albuquerque TR et al. J Cereb Blood Flow Metab. 2022;42(12):2175–2187.
- Cardona-Acosta AM et al. Biol Psychiatry. 2025.
- Chen BK, Denny CA. Neuropharmacology. 2023;224:109345.